Amon R. Wafelman

2.5k citations

23 papers · 2.0k indexed · 1 hit paper · h-index 14

Co-authors: Jan W. Drijfhout A. Rob P.M. Valentijn Sjoerd H. van der Burg Cornelis J.M. Melief Gert Jan Fleuren Gemma G. Kenter Rienk Offringa Marij J.P. Welters
Topics: Radiopharmaceutical Chemistry and Applications (7 papers)Medical Imaging Techniques and Applications (6 papers)Cervical Cancer and HPV Research (5 papers)
Cited by: Immunology Microbiology Oncology
Journals: New England Journal of Medicine Blood PLoS ONE
Partner nations: Netherlands Czechia United States

In The Last Decade

Amon R. Wafelman

23 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

2009 803 citations Gemma G. Kenter, Marij J.P. Welters et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Amon R. Wafelman

Since Specialization

Citations

This map shows the geographic impact of Amon R. Wafelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amon R. Wafelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amon R. Wafelman more than expected).

Fields of papers citing papers by Amon R. Wafelman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amon R. Wafelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amon R. Wafelman. The network helps show where Amon R. Wafelman may publish in the future.

Co-authorship network of co-authors of Amon R. Wafelman

This figure shows the co-authorship network connecting the top 25 collaborators of Amon R. Wafelman. A scholar is included among the top collaborators of Amon R. Wafelman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amon R. Wafelman. Amon R. Wafelman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ototopical drops containing a novel antibacterial synthetic peptide: Safety and efficacy in adults with chronic suppurative otitis media 2020 ·PLoS ONE ·(unknown),(unknown),Ronald Brand,(unknown),Ewoud J. van Hoogdalem,R. Verrijk,(unknown),Amon R. Wafelman,A. Rob P.M. Valentijn,Johan H. M. Frijns,Pieter S. Hiemstra,Jan W. Drijfhout,Peter H. Nibbering,J. J. Grote	25
2	Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study 2012 ·Haematologica ·Pauline Meij,Inge Jedema,Menno A. W. G. van der Hoorn,(unknown),Laura A. Cox,Amon R. Wafelman,Erik W.A. Marijt,Rein Willemze,J.H. Frederik Falkenburg	42
3	Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasiabreakdown → 2009 ·New England Journal of Medicine ·Gemma G. Kenter,Marij J.P. Welters,A. Rob P.M. Valentijn,Margriet J. Löwik,Dorien M. A. Berends-van der Meer,Annelies P.G. Vloon,(unknown),Lorraine M. Fathers,Rienk Offringa,Jan W. Drijfhout,Amon R. Wafelman,Jaap Oostendorp,Gert Jan Fleuren,Sjoerd H. van der Burg,Cornelis J.M. Melief	803
4	Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16 2008 ·Cornelis J.M. Melief,Marij J.P. Welters,Margriet J. Löwik,Annelies P.G. Vloon,Jan W. Drijfhout,A. Rob P.M. Valentijn,Amon R. Wafelman,Gert Jan Fleuren,Rienk Offringa,Sjoerd H. van der Burg,Gemma G. Kenter	1
5	Symposium report—Development of safe protein therapeutics: Pre-clinical, clinical and regulatory issues 2008 ·European Journal of Pharmaceutical Sciences ·Amon R. Wafelman	1
6	Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia 2008 ·International Journal of Cancer ·Muriel van den Hende,Mariëtte I.E. van Poelgeest,Jeanette M. van der Hulst,Joan de Jong,Jan W. Drijfhout,Gert Jan Fleuren,A. Rob P.M. Valentijn,Amon R. Wafelman,(unknown),Cornelis J.M. Melief,Rienk Offringa,Sjoerd H. van der Burg,Gemma G. Kenter	34
7	Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity 2008 ·Clinical Cancer Research ·Gemma G. Kenter,Marij J.P. Welters,A. Rob P.M. Valentijn,(unknown),Dorien M. A. Berends-van der Meer,Annelies P.G. Vloon,Jan W. Drijfhout,Amon R. Wafelman,Jaap Oostendorp,Gert Jan Fleuren,Rienk Offringa,Sjoerd H. van der Burg,Cornelis J.M. Melief	246
8	Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine 2008 ·Clinical Cancer Research ·Marij J.P. Welters,Gemma G. Kenter,Sytse J. Piersma,Annelies P.G. Vloon,(unknown),Dorien M. A. Berends-van der Meer,Jan W. Drijfhout,A. Rob P.M. Valentijn,Amon R. Wafelman,Jaap Oostendorp,Gert Jan Fleuren,Rienk Offringa,Cornelis J.M. Melief,Sjoerd H. van der Burg	310
9	Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation 2007 ·Haematologica ·Erik W.A. Marijt,Amon R. Wafelman,(unknown),Cornelis A.M. van Bergen,(unknown),(unknown),(unknown),(unknown),(unknown),R. Willemze,F. Falkenburg	36
10	Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application 2005 ·Peptides ·(unknown),G. Sandra Tjabringa,Amon R. Wafelman,R. Verrijk,Pieter S. Hiemstra,Jan W. Drijfhout,J. J. Grote	154
11	Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes 1999 ·Blood ·J.H. Frederik Falkenburg,Amon R. Wafelman,Peter Joosten,Willem M. Smit,Cornelis A.M. van Bergen,(unknown),Ellie G.A. Lurvink,(unknown),Petra Kluck,J. E. Landegent,Hanneke C. Kluin‐Nelemans,Willem E. Fibbe,Roel Willemze	13
12	Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes 1999 ·Blood ·J.H. Frederik Falkenburg,Amon R. Wafelman,Peter Joosten,Willem M. Smit,Cornelis A.M. van Bergen,(unknown),Ellie G.A. Lurvink,(unknown),Petra Kluck,J. E. Landegent,Hanneke C. Kluin‐Nelemans,Willem E. Fibbe,Roel Willemze	224
13	Renal excretion of iodine-131 labelledmeta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours 1997 ·European Journal of Nuclear Medicine and Molecular Imaging ·Amon R. Wafelman,Cornelis A. Hoefnagel,(unknown),R. A. A. Maes,(unknown)	20
14	Bioanalysis of radioiodine labelled meta-iodobenzylguanidine, its metabolites and free radioiodide in body fluids 1997 ·European Journal of Pharmaceutical Sciences ·Amon R. Wafelman,Cornelis A. Hoefnagel,R. A. A. Maes,Jos H. Beijnen	2
15	Radiochemical Purity, at Expiry, and Radiochemical Stability of Iodine-131 Labelled Meta-iodobenzylguanidine Concentrates for Intravenous Infusion 1996 ·Nuklearmedizin - NuclearMedicine ·Cornelis A. Hoefnagel,R. A. A. Maes,(unknown),Amon R. Wafelman	6
16	Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance 1995 ·Nuclear Medicine Communications ·Amon R. Wafelman,(unknown),Hilde Rosing,(unknown),B.G. Taal,Cornelis A. Hoefnagel,R. A. A. Maes,(unknown)	18
17	High-performance liquid chromatographic determination of metaiodobenzylguanidine in whole blood and plasma of cancer patients 1994 ·Journal of Pharmaceutical and Biomedical Analysis ·Amon R. Wafelman,(unknown),Hilde Rosing,Cornelis A. Hoefnagel,B.G. Taal,R. A. A. Maes,Jos H. Beijnen	3
18	Synthesis, radiolabelling and stability of radioiodinated m-iodobenzylguanidine, a review 1994 ·Applied Radiation and Isotopes ·Amon R. Wafelman,(unknown),Cornelis A. Hoefnagel,R. A. A. Maes,J. H. Beijnen	22
19	High-performance liquid chromatographic determination of m-iodobenzylguanidine in urine of cancer patients 1993 ·Journal of Chromatography B Biomedical Sciences and Applications ·Amon R. Wafelman,(unknown),Hilde Rosing,W.J.M. Underberg,R. A. A. Maes,Jos H. Beijnen	3
20	Radiochemical stability during infusion of 131I-labelled metaiodobenzylguanidine for therapeutic use 1993 ·Nuclear Medicine Communications ·Amon R. Wafelman,Cornelis A. Hoefnagel,Jos H. Beijnen	14

About Amon R. Wafelman

Amon R. Wafelman is a scholar working on Virology, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 23 papers that have together received 2.0k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (7 papers), Medical Imaging Techniques and Applications (6 papers) and Cervical Cancer and HPV Research (5 papers). The work is most often cited by research in Immunology (1.4k citations), Microbiology (210 citations) and Oncology (788 citations). Amon R. Wafelman has collaborated with scholars based in Netherlands, Czechia and United States. Frequent co-authors include Jan W. Drijfhout, A. Rob P.M. Valentijn, Sjoerd H. van der Burg, Cornelis J.M. Melief, Gert Jan Fleuren, Gemma G. Kenter, Rienk Offringa, Marij J.P. Welters, Annelies P.G. Vloon and Jaap Oostendorp. Their work appears in journals such as New England Journal of Medicine, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact